{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["A disintegrin and metalloprotease", "Breast cancer", "Metastasis", "Treatment"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38317965", "DateRevised": {"Year": "2024", "Month": "03", "Day": "01"}, "Article": {"Language": ["eng"], "ELocationID": ["e24805", "10.1016/j.heliyon.2024.e24805"], "ArticleDate": [{"Year": "2024", "Month": "01", "Day": "19"}], "Journal": {"ISSN": "2405-8440", "JournalIssue": {"Volume": "10", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Feb", "Day": "15"}}, "Title": "Heliyon", "ISOAbbreviation": "Heliyon"}, "ArticleTitle": "New insight into the role of the ADAM protease family in breast carcinoma progression.", "Pagination": {"StartPage": "e24805", "MedlinePgn": "e24805"}, "Abstract": {"AbstractText": ["Protease and adhesion molecules play a very emphasized role in the occurrence or progression of metastasis in many types of cancers. In this context, a molecule that contains both protease and adhesion functions play a crucial role in metastasis. ADAMs (a disintegrin and metalloprotease) are molecules with this special characteristic. Recently, a lot of attention has been attracted to various ADAM molecules and researchers have tried to elucidate the role of ADAMs in breast cancer occurrence and progression. Disrupting ADAMs protease and adhesion capabilities can lead to the discovery of worthy therapeutic targets in breast cancer treatment. In this review, we intend to discuss the mechanism of action of various ADAM molecules, their relation to pathogenic processes of breast cancer, and their potential as possible targets for breast cancer treatment."], "CopyrightInformation": "\u00a9 2024 The Authors."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran."}], "LastName": "Navasatli", "ForeName": "Sepideh Aliniaye", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran."}], "LastName": "Vahdati", "ForeName": "Saeed Niazi", "Initials": "SN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran."}], "LastName": "Arjmand", "ForeName": "Tahura Fayeghi", "Initials": "TF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran."}], "LastName": "Mohammadi Far", "ForeName": "Marjan", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran."}], "LastName": "Behboudi", "ForeName": "Hossein", "Initials": "H"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Heliyon", "NlmUniqueID": "101672560", "ISSNLinking": "2405-8440"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Stewart B., Wild C.  International Agency for Research on Cancer; Lyon, France: 2019. World Cancer Report 2014.http://publications.iarc.fr/Non-Series IARC Publications Website:"}, {"Citation": "Romagnoli M., Mineva N.D., Polmear M., Conrad C., Srinivasan S., Loussouarn D., et al. ADAM 8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol. Med. 2014;6(2):278\u2013294.", "ArticleIdList": ["PMC3927960", "24375628"]}, {"Citation": "De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003;200(4):429\u2013447.", "ArticleIdList": ["12845611"]}, {"Citation": "Zigrino P., Loffek S., Mauch C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie. 2005;87(3\u20134):321\u2013328.", "ArticleIdList": ["15781319"]}, {"Citation": "Fowlkes J.L., Thrailkill K.M., Serra D.M., Suzuki K., Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog. Growth Factor Res. 1995;6(2\u20134):255\u2013263.", "ArticleIdList": ["8817668"]}, {"Citation": "Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996;271(17):10079\u201310086.", "ArticleIdList": ["8626565"]}, {"Citation": "Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gene Dev. 2000;14(2):163\u2013176.", "ArticleIdList": ["PMC316345", "10652271"]}, {"Citation": "Mizgerd J.P., Spieker M.R., Doerschuk C.M. Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. J. Immunol. 2001;166(6):4042\u20134048.", "ArticleIdList": ["11238652"]}, {"Citation": "Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer. 2008;8(12):929\u2013941.", "ArticleIdList": ["19005493"]}, {"Citation": "Gaultier A., Cousin H., Darribere T., Alfandari D. ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin. J. Biol. Chem. 2002;277(26):23336\u201323344.", "ArticleIdList": ["11967265"]}, {"Citation": "Iba K., Albrechtsen R., Gilpin B., Frohlich C., Loechel F., Zolkiewska A., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J. Cell Biol. 2000;149(5):1143\u20131156.", "ArticleIdList": ["PMC2174829", "10831617"]}, {"Citation": "Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Gene Dev. 2003;17(1):7\u201330.", "ArticleIdList": ["12514095"]}, {"Citation": "Wang H., Wu H., Chen Y. Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer. Clin. Transl. Oncol. 2023;25(2):473\u2013481.", "ArticleIdList": ["36183312"]}, {"Citation": "Emi M., Katagiri T., Harada Y., Saito H., Inazawa J., Ito I., et al. A novel metalloprotease/disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nat. Genet. 1993;5(2):151\u2013157.", "ArticleIdList": ["8252040"]}, {"Citation": "Iba K., Albrechtsen R., Gilpin B.J., Loechel F., Wewer U.M. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am. J. Pathol. 1999;154(5):1489\u20131501.", "ArticleIdList": ["PMC1866592", "10329602"]}, {"Citation": "Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 2005;6(1):32\u201343.", "ArticleIdList": ["15688065"]}, {"Citation": "Duffy M.J., Lynn D.J., Lloyd A.T., O'Shea C.M. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb. Haemostasis. 2003;89(4):622\u2013631.", "ArticleIdList": ["12669115"]}, {"Citation": "Asai M., Hattori C., Szabo B., Sasagawa N., Maruyama K., Tanuma S., et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem. Biophys. Res. Commun. 2003;301(1):231\u2013235.", "ArticleIdList": ["12535668"]}, {"Citation": "Tian B.L., Wen J.M., Zhang M., Xie D., Xu R.B., Luo C.J. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. Mol. Pathol. : M. Inc. 2002;55(6):394\u2013397.", "ArticleIdList": ["PMC1187278", "12456779"]}, {"Citation": "Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., Warn A., et al. Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma. Mol. Cancer Res. : MCR. 2008;6(3):383\u2013394.", "ArticleIdList": ["18296648"]}, {"Citation": "Mitsui Y., Mochizuki S., Kodama T., Shimoda M., Ohtsuka T., Shiomi T., et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006;66(20):9913\u20139920.", "ArticleIdList": ["17047053"]}, {"Citation": "Jia L.G., Shimokawa K., Bjarnason J.B., Fox J.W. Snake venom metalloproteinases: structure, function and relationship to the ADAMs family of proteins. Toxicon : official journal of the International Society on Toxinology. 1996;34(11\u201312):1269\u20131276.", "ArticleIdList": ["9027982"]}, {"Citation": "Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11(11):S37\u2013S43.", "ArticleIdList": ["PMC2788992", "11684441"]}, {"Citation": "Costa F.F., Verbisck N.V., Salim A.C., Ierardi D.F., Pires L.C., Sasahara R.M., et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene. 2004;23(7):1481\u20131488.", "ArticleIdList": ["14661055"]}, {"Citation": "Martin J., Eynstone L.V., Davies M., Williams J.D., Steadman R. The role of ADAM 15 in glomerular mesangial cell migration. J. Biol. Chem. 2002;277(37):33683\u201333689.", "ArticleIdList": ["12091380"]}, {"Citation": "Alfandari D., Cousin H., Gaultier A., Smith K., White J.M., Darribere T., et al. Xenopus ADAM 13 is a metalloprotease required for cranial neural crest-cell migration. Curr. Biol. : CB. 2001;11(12):918\u2013930.", "ArticleIdList": ["11448768"]}, {"Citation": "McGowan P.M., Ryan B.M., Hill A.D., McDermott E., O'Higgins N., Duffy M.J. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin. Cancer Res. : an official journal of the American Association for Cancer Research. 2007;13(8):2335\u20132343.", "ArticleIdList": ["17438092"]}, {"Citation": "Fabre-Lafay S., Garrido-Urbani S., Reymond N., Goncalves A., Dubreuil P., Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J. Biol. Chem. 2005;280(20):19543\u201319550.", "ArticleIdList": ["15784625"]}, {"Citation": "Zhang X.P., Kamata T., Yokoyama K., Puzon-McLaughlin W., Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J. Biol. Chem. 1998;273(13):7345\u20137350.", "ArticleIdList": ["9516430"]}, {"Citation": "Lendeckel U., Kohl J., Arndt M., Carl-McGrath S., Donat H., Rocken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J. Cancer Res. Clin. Oncol. 2005;131(1):41\u201348.", "ArticleIdList": ["15565459"]}, {"Citation": "Quaranta V., Giannelli G. Cancer invasion: watch your neighbourhood. Tumori. 2003;89(4):343\u2013348.", "ArticleIdList": ["14606634"]}, {"Citation": "Slack R.J., Macdonald S.J., Roper J.A., Jenkins R.G., Hatley R.J. Emerging therapeutic opportunities for integrin inhibitors. Nat. Rev. Drug Discov. 2022;21(1):60\u201378.", "ArticleIdList": ["PMC8446727", "34535788"]}, {"Citation": "Schuppan D., Ocker M. Integrin-mediated control of cell growth. Hepatology. 2003;38(2):289\u2013291.", "ArticleIdList": ["12883471"]}, {"Citation": "Nath D., Slocombe P.M., Stephens P.E., Warn A., Hutchinson G.R., Yamada K.M., et al. Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J. Cell Sci. 1999;112(Pt 4):579\u2013587.", "ArticleIdList": ["9914169"]}, {"Citation": "Werb Z., Yan Y. A cellular striptease act. Science (New York, NY) 1998;282(5392):1279\u20131280.", "ArticleIdList": ["9867633"]}, {"Citation": "Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science (New York, NY) 1998;282(5392):1281\u20131284.", "ArticleIdList": ["9812885"]}, {"Citation": "Conrad C., G\u00f6tte M., Schlomann U., Roessler M., Pagenstecher A., Anderson P., et al. ADAM8 expression in breast cancer derived brain metastases: functional implications on MMP\u20109 expression and transendothelial migration in breast cancer cells. Int. J. Cancer. 2018;142(4):779\u2013791.", "ArticleIdList": ["28986926"]}, {"Citation": "Lahlou H., Muller W.J. \u03b21-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res. 2011;13(6):1\u201310.", "ArticleIdList": ["PMC3326542", "22264244"]}, {"Citation": "Fry J.L., Toker A. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 2010;70(20):8187\u20138198.", "ArticleIdList": ["PMC2955804", "20736367"]}, {"Citation": "O'Shea C., McKie N., Buggy Y., Duggan C., Hill A.D., McDermott E., et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int. J. Cancer. 2003;105(6):754\u2013761.", "ArticleIdList": ["12767059"]}, {"Citation": "Fischer O.M., Hart S., Gschwind A., Prenzel N., Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol. Cell Biol. 2004;24(12):5172\u20135183.", "ArticleIdList": ["PMC419881", "15169883"]}, {"Citation": "Itabashi H., Maesawa C., Oikawa H., Kotani K., Sakurai E., Kato K., et al. Angiotensin II and epidermal growth factor receptor cross\u2010talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol. Res. 2008;38(6):601\u2013613.", "ArticleIdList": ["18452483"]}, {"Citation": "Newton R.C., Bradley E.C., Levy R.S., Doval D., Bondarde S., Sahoo T.P., et al. Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+breast cancer. J. Clin. Oncol. 2010;28(15)"}, {"Citation": "Liu P.C., Liu X., Li Y., Covington M., Wynn R., Huber R., et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 2006;5(6):657\u2013664.", "ArticleIdList": ["16627989"]}, {"Citation": "Scherle P., Liu X., Li J., Fridman J., Li Y., Yao W., Williams W., Levy R., Vaddi K., Newton R., Friedman S. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. J. Clin. Oncol. 2006;24(18_suppl)", "ArticleIdList": ["16627988"]}, {"Citation": "Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999;59(6):1196\u20131201.", "ArticleIdList": ["10096547"]}, {"Citation": "Rose A.A., Annis M.G., Dong Z., Pepin F., Hallett M., Park M., Siegel P.M. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One. 2010;5(8)", "ArticleIdList": ["PMC2919417", "20711474"]}, {"Citation": "Romero Y., Wise R., Zolkiewska A. Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. Cancer Immunol. Immunother. 2020;69(1):43\u201355.", "ArticleIdList": ["PMC6952561", "31796994"]}, {"Citation": "Katagiri T., Harada Y., Emi M., Nakamura Y. Human metalloprotease/disintegrin-like (MDC) gene: exon-intron organization and alternative splicing. Cytogenet. Cell Genet. 1995;68(1\u20132):39\u201344.", "ArticleIdList": ["7956356"]}, {"Citation": "Kveiborg M., Frohlich C., Albrechtsen R., Tischler V., Dietrich N., Holck P., et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 2005;65(11):4754\u20134761.", "ArticleIdList": ["15930294"]}, {"Citation": "Ray A., Dhar S., Ray B.K. Transforming growth factor-beta1-mediated activation of NF-kappaB contributes to enhanced ADAM-12 expression in mammary carcinoma cells. Mol. Cancer Res. : MCR. 2010;8(9):1261\u20131270.", "ArticleIdList": ["20688878"]}, {"Citation": "Li H., Duhachek-Muggy S., Qi Y., Hong Y., Behbod F., Zolkiewska A. An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer. Breast Cancer Res. Treat. 2012;135(3):759\u2013769.", "ArticleIdList": ["PMC3470813", "22926263"]}, {"Citation": "Duhachek-Muggy S., Qi Y., Wise R., Alyahya L., Li H., Hodge J., et al. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Mol. Cancer. 2017;16(1):32.", "ArticleIdList": ["PMC5288940", "28148288"]}, {"Citation": "Wang G., Romero Y., Thevarajan I., Zolkiewska A. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer. OncoImmunology. 2023;12(1)", "ArticleIdList": ["PMC9762783", "36545255"]}, {"Citation": "Brown R.V., Gaerig V.C., Simmons T., Brooks T.A. Helping Eve overcome ADAM: G-quadruplexes in the ADAM-15 promoter as new molecular targets for breast cancer therapeutics. Molecules. 2013;18(12):15019\u201315034.", "ArticleIdList": ["PMC6270510", "24317528"]}, {"Citation": "Mattern J., Roghi C.S., Hurtz M., Knauper V., Edwards D.R., Poghosyan Z. ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells. Sci. Rep. 2019;9(1)", "ArticleIdList": ["PMC6715704", "31467400"]}, {"Citation": "Narita D., Seclaman E., Ilina R., Cireap N., Ursoniu S., Anghel A. ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors. Pathol. Oncol. Res. 2011;17(2):375\u2013385.", "ArticleIdList": ["21240579"]}, {"Citation": "Black R.A. Tumor necrosis factor-alpha converting enzyme. Int. J. Biochem. Cell Biol. 2002;34(1):1\u20135.", "ArticleIdList": ["11733179"]}, {"Citation": "Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729\u2013733.", "ArticleIdList": ["9034190"]}, {"Citation": "Borrell-Pages M., Rojo F., Albanell J., Baselga J., Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J. 2003;22(5):1114\u20131124.", "ArticleIdList": ["PMC150344", "12606576"]}, {"Citation": "Zheng Y., Saftig P., Hartmann D., Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17) J. Biol. Chem. 2004;279(41):42898\u201342906.", "ArticleIdList": ["15292243"]}, {"Citation": "Kawaguchi N., Horiuchi K., Becherer J.D., Toyama Y., Besmer P., Blobel C.P. Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. J. Cell Sci. 2007;120(Pt 6):943\u2013952.", "ArticleIdList": ["17344430"]}, {"Citation": "Hinkle C.L., Sunnarborg S.W., Loiselle D., Parker C.E., Stevenson M., Russell W.E., et al. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J. Biol. Chem. 2004;279(23):24179\u201324188.", "ArticleIdList": ["15066986"]}, {"Citation": "Sunnarborg S.W., Hinkle C.L., Stevenson M., Russell W.E., Raska C.S., Peschon J.J., et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol. Chem. 2002;277(15):12838\u201312845.", "ArticleIdList": ["11823465"]}, {"Citation": "Rovida E., Paccagnini A., Del Rosso M., Peschon J., Dello Sbarba P. TNF-\u03b1-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J. Immunol. 2001;166(3):1583\u20131589.", "ArticleIdList": ["11160199"]}, {"Citation": "Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19(56):6642\u20136650.", "ArticleIdList": ["11426650"]}, {"Citation": "Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006;10(1):39\u201350.", "ArticleIdList": ["PMC4451119", "16843264"]}, {"Citation": "Liu X., Fridman J.S., Wang Q., Caulder E., Yang G., Covington M., et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol. Ther. 2006;5(6):648\u2013656.", "ArticleIdList": ["16627988"]}, {"Citation": "Fridman J.S., Caulder E., Hansbury M., Liu X., Yang G., Wang Q., et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin. Cancer Res. : an official journal of the American Association for Cancer Research. 2007;13(6):1892\u20131902.", "ArticleIdList": ["17363546"]}, {"Citation": "Pham D.H., Kim J.S., Kim S.K., Shin D.J., Uong N.T., Hyun H., et al. Effects of ADAM10 and ADAM17 inhibitors on natural killer cell expansion and antibody-dependent cellular cytotoxicity against breast cancer cells in vitro. Anticancer Res. 2017;37(10):5507\u20135513.", "ArticleIdList": ["28982863"]}, {"Citation": "Kang T.Z.E., Zhu L., Yang D., Ding D., Zhu X., Wan Y.C.E., et al. The elevated transcription of ADAM19 by the oncohistone H2BE76K contributes to oncogenic properties in breast cancer. J. Biol. Chem. 2021;296", "ArticleIdList": ["PMC7949156", "33548228"]}, {"Citation": "McCartan D., Bolger J.C., Fagan A., Byrne C., Hao Y., Qin L., et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res. 2012;72(1):220\u2013229.", "ArticleIdList": ["PMC3681815", "22072566"]}, {"Citation": "Bolger J.C., Young L.S. ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer. Vitam. Horm. 2013;93:307\u2013321.", "ArticleIdList": ["23810013"]}, {"Citation": "Cal S., Freije J.M., Lopez J.M., Takada Y., Lopez-Otin C. ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism. Mol. Biol. Cell. 2000;11(4):1457\u20131469.", "ArticleIdList": ["PMC14859", "10749942"]}, {"Citation": "Kalinkova L., Zmetakova I., Smolkova B., Minarik G., Sedlackova T., Horvathova Kajabova V., et al. Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers. BMC Cancer. 2018;18(1):875.", "ArticleIdList": ["PMC6127923", "30189837"]}, {"Citation": "Zhao M., Jia W., Jiang W.G., Wang P., Du G., Cheng S., et al. ADAM29 expression in human breast cancer and its effects on breast cancer cells in vitro. Anticancer Res. 2016;36(3):1251\u20131258.", "ArticleIdList": ["26977022"]}, {"Citation": "Seniski G.G., Camargo A.A., Ierardi D.F., Ramos E.A., Grochoski M., Ribeiro E.S., et al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 2009;9:80.", "ArticleIdList": ["PMC2660367", "19267929"]}, {"Citation": "Fang S., Zhao Y., Hu X. LncRNA ADAMTS9-AS1 restrains the aggressive traits of breast carcinoma cells via sponging miR-513a-5p. Cancer Manag. Res. 2020;12:10693\u201310703.", "ArticleIdList": ["PMC7604470", "33149676"]}, {"Citation": "Chen Q., Xu H., Zhu J., Feng K., Hu C. LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis. Biomed. Pharmacother. 2020;128", "ArticleIdList": ["32485570"]}, {"Citation": "Kim J., Piao H.-L., Kim B.-J., Yao F., Han Z., Wang Y., et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat. Genet. 2018;50(12):1705\u20131715.", "ArticleIdList": ["PMC6265076", "30349115"]}, {"Citation": "Conrad C., Gotte M., Schlomann U., Roessler M., Pagenstecher A., Anderson P., et al. ADAM8 expression in breast cancer derived brain metastases: functional implications on MMP-9 expression and transendothelial migration in breast cancer cells. Int. J. Cancer. 2018;142(4):779\u2013791.", "ArticleIdList": ["28986926"]}, {"Citation": "Das S.G., Romagnoli M., Mineva N.D., Barill\u00e9-Nion S., J\u00e9z\u00e9quel P., Campone M., et al. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells. Breast Cancer Res. 2016;18:1\u201319.", "ArticleIdList": ["PMC4818899", "27039296"]}, {"Citation": "Sieuwerts A.M., Meijer-van Gelder M.E., Timmermans M., Trapman A.M., Garcia R.R., Arnold M., et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin. Cancer Res. : an official journal of the American Association for Cancer Research. 2005;11(20):7311\u20137321.", "ArticleIdList": ["16243802"]}, {"Citation": "Micocci K.C., Martin A.C., Montenegro Cde F., Durante A.C., Pouliot N., Cominetti M.R., et al. ADAM9 silencing inhibits breast tumor cell invasion in vitro. Biochimie. 2013;95(7):1371\u20131378.", "ArticleIdList": ["23499592"]}, {"Citation": "Micocci K.C., Moritz M.N., Lino R.L., Fernandes L.R., Lima A.G., Figueiredo C.C., et al. ADAM9 silencing inhibits breast tumor cells transmigration through blood and lymphatic endothelial cells. Biochimie. 2016;128\u2013129:174\u2013182.", "ArticleIdList": ["27554339"]}, {"Citation": "Wang J.J., Zou J.X., Wang H., Duan Z.J., Wang H.B., Chen P., et al. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling. Acta Pharmacol. Sin. 2019;40(8):1067\u20131075.", "ArticleIdList": ["PMC6786427", "30670815"]}, {"Citation": "Gareus R., Di Nardo A., Rybin V., Witke W. Mouse profilin 2 regulates endocytosis and competes with SH3 ligand binding to dynamin 1. J. Biol. Chem. 2006;281(5):2803\u20132811.", "ArticleIdList": ["16319076"]}, {"Citation": "Schluter K., Jockusch B.M., Rothkegel M. Profilins as regulators of actin dynamics. Biochim. Biophys. Acta Mol. Cell Res. 1997;1359(2):97\u2013109.", "ArticleIdList": ["9409807"]}, {"Citation": "Xu C., Yu H., Yin X., Zhang J., Liu C., Qi H., et al. Circular RNA circNINL promotes breast cancer progression through activating beta-catenin signaling via miR-921/ADAM9 axis. J. Biochem. 2021;169(6):693\u2013700.", "ArticleIdList": ["33479730"]}, {"Citation": "De Marchis L., Cropp C., Sheng Z.M., Bargo S., Callahan R. Candidate target genes for loss of heterozygosity on human chromosome 17q21. Br. J. Cancer. 2004;90(12):2384\u20132389.", "ArticleIdList": ["PMC2409524", "15187990"]}, {"Citation": "Orsetti B., Nugoli M., Cervera N., Lasorsa L., Chuchana P., Ursule L., et al. Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res. 2004;64(18):6453\u20136460.", "ArticleIdList": ["15374954"]}, {"Citation": "Kveiborg M., Albrechtsen R., Couchman J.R., Wewer U.M. Cellular roles of ADAM12 in health and disease. Int. J. Biochem. Cell Biol. 2008;40(9):1685\u20131702.", "ArticleIdList": ["18342566"]}, {"Citation": "Wewer U.M., Morgelin M., Holck P., Jacobsen J., Lydolph M.C., Johnsen A.H., et al. ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. J. Biol. Chem. 2006;281(14):9418\u20139422.", "ArticleIdList": ["16455653"]}, {"Citation": "Narita D., Seclaman E., Ursoniu S., Anghel A. Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. Acta Histochem. 2012;114(2):131\u2013139.", "ArticleIdList": ["21501859"]}, {"Citation": "Stautz D., Wewer U.M., Kveiborg M. Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12. PLoS One. 2012;7(5)", "ArticleIdList": ["PMC3360752", "22662180"]}, {"Citation": "Ortiz R.M., Karkkainen I., Huovila A.P. Aberrant alternative exon use and increased copy number of human metalloprotease-disintegrin ADAM15 gene in breast cancer cells. Gene Chromosome Cancer. 2004;41(4):366\u2013378.", "ArticleIdList": ["15384173"]}, {"Citation": "McGowan P.M., McKiernan E., Bolster F., Ryan B.M., Hill A.D., McDermott E.W., et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann. Oncol. : official journal of the European Society for Medical Oncology. 2008;19(6):1075\u20131081.", "ArticleIdList": ["18238782"]}, {"Citation": "Caiazza F., McGowan P.M., Mullooly M., Murray A., Synnott N., O'Donovan N., et al. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br. J. Cancer. 2015;112(12):1895\u20131903.", "ArticleIdList": ["PMC4580380", "26010411"]}, {"Citation": "Lemjabbar H., Li D., Gallup M., Sidhu S., Drori E., Basbaum C. Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J. Biol. Chem. 2003;278(28):26202\u201326207.", "ArticleIdList": ["12711607"]}, {"Citation": "Gschwind A., Hart S., Fischer O.M., Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 2003;22(10):2411\u20132421.", "ArticleIdList": ["PMC155989", "12743035"]}, {"Citation": "Schafer B., Marg B., Gschwind A., Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J. Biol. Chem. 2004;279(46):47929\u201347938.", "ArticleIdList": ["15337756"]}, {"Citation": "Schafer B., Gschwind A., Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene. 2004;23(4):991\u2013999.", "ArticleIdList": ["14647423"]}, {"Citation": "Venook A.P. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer. 2005;103(12):2435\u20132446.", "ArticleIdList": ["15880563"]}, {"Citation": "Sinnathamby G., Zerfass J., Hafner J., Block P., Nickens Z., Hobeika A., et al. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin. Exp. Immunol. 2011;163(3):324\u2013332.", "ArticleIdList": ["PMC3048615", "21175594"]}, {"Citation": "Horiuchi K., Le Gall S., Schulte M., Yamaguchi T., Reiss K., Murphy G., et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol. Biol. Cell. 2007;18(1):176\u2013188.", "ArticleIdList": ["PMC1751309", "17079736"]}, {"Citation": "Yang P.J., Hou M.F., Tsai E.M., Liang S.S., Chiu C.C., Ou-Yang F., et al. Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain 33 (ADAM33) gene affected by endocrine-disrupting chemicals. Oncol. Rep. 2018;40(5):2766\u20132777.", "ArticleIdList": ["30226539"]}, {"Citation": "Roy D.M., Walsh L.A. Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer. 2014:81\u201391.", "ArticleIdList": ["PMC4090043", "25114586"]}, {"Citation": "McFadden M., Singh S.K., Oprea-Ilies G., Singh R. Nano-based drug delivery and targeting to overcome drug resistance of ovarian cancers. Cancers. 2021;13(21):5480.", "ArticleIdList": ["PMC8582784", "34771642"]}]}], "History": [{"Year": "2023", "Month": "8", "Day": "13"}, {"Year": "2024", "Month": "1", "Day": "13"}, {"Year": "2024", "Month": "1", "Day": "15"}, {"Year": "2024", "Month": "2", "Day": "6", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "2", "Day": "6", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "2", "Day": "6", "Hour": "3", "Minute": "50"}, {"Year": "2024", "Month": "1", "Day": "19"}], "PublicationStatus": "epublish", "ArticleIdList": ["38317965", "PMC10839977", "10.1016/j.heliyon.2024.e24805", "S2405-8440(24)00836-3"]}}]}